GlassScriptPhysician profile
Antonio R Parente
NPI 1366444523
$2,370.60
in general payments reported to CMS, 2019-2025
26 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $94.93 · 2022: $118 · 2023: $313 · 2024: $466 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $451.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $361.83 | 2019-2025 | |
| Amgen INC. | $337.10 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $166.72 | 2019-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $160.62 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $127.19 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $125.35 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $85.41 | 2019-2025 | Wainua |
| Kowa Pharmaceuticals America, INC. | $47.47 | 2019 | |
| Amarin Pharma, INC. | $46.93 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $44.59 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.02 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $39.28 | 2019-2023 | |
| Esperion Therapeutics, INC. | $38.87 | 2024-2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $37.97 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $34.65 | 2019 | |
| Lilly USA, LLC | $31.71 | 2025 | Zepbound |
| Tactile Systems Technology INC | $30.35 | 2019-2023 | Flexitouch Plus, Entre Plus |
| Actelion Pharmaceuticals US, INC. | $26.44 | 2025 | Opsumit |
| Abbott Laboratories | $24.80 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $22.85 | 2023 | Arcalyst |
| Novo Nordisk INC | $18.47 | 2022 | |
| Bridgebio Pharma, INC. | $18.36 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $17.97 | 2024 | Assure Wcd |
| Astellas Pharma US INC | $15.78 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Parente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.